CFS/ME remain elusive illnesses which require a thorough medical and psychiatric work-up to exclude treatable conditions before the diagnosis can be established. In contrast to what some people and even health care providers believe, CFS/ME is not a psychiatric or so called "psychosomatic illness", indicating that a cause should be looked for in psychosocial factors.
It is rather a very complex, multifactorial syndrome in which the central nervous system, the autonomous nervous system, the endocrine system and the immune system (and the communication between these systems), are malfunctioning severely. Patients are severely impaired in their quality of life and their functioning.
Currently, no clear cause has been identified and as in most complex illnesses, it is most likely multifactorial. The population and the course of the illness is very heterogeneous and no definite treatment, other than managing symptoms has been identified.
In this powerpoint, a current overview of how the diagnosis should be established is given and an overview of the current pathophysiological findings, as well as the therapeutic posibilities, are discussed briefly.
Chronic fatigue syndrome (CFS) is a disorder characterized by severe fatigue lasting over 6 months along with cognitive difficulties. It affects women more than men and those who are overweight and inactive. While the cause is unknown, it may be related to viral infections. The diagnosis is made after excluding other conditions and involves fatigue, impaired memory/concentration, sore throat, tender lymph nodes, muscle/joint pain, headaches, and unrefreshing sleep. Management focuses on symptom relief through analgesics, antidepressants, and sedatives as well as improving quality of life through sleep, rest, and relaxation techniques. Specific treatments have not proven effective.
This document provides an overview of chronic fatigue syndrome (CFS), including its symptoms, diagnosis, and living with the condition. CFS is a complex illness characterized by severe fatigue and other symptoms like muscle pain and cognitive impairment that are worsened by physical or mental activity. While the cause is unknown, diagnosis involves ruling out other conditions and having specific symptoms for at least 6 months. Managing CFS requires an individualized treatment plan and coping strategies, as living with a fluctuating condition can be difficult both physically and emotionally.
Post covid-19 syndrome, also known as long covid, refers to symptoms that can persist for weeks or months after recovery from the initial acute illness. While people are not infectious during this time, there is no agreed upon definition. A wide range of long-term symptoms have been reported, including fatigue, chest pain, muscle pain, loss of smell, and depression. Certain groups, such as older individuals, those who are obese, and people with diabetes or lung/kidney disease, appear to be at higher risk of developing long-term effects from covid-19.
This document discusses bronchiectasis, defined as abnormal permanent dilation of the bronchi. It covers the types (tubular, varicose, cystic), diagnosis (clinical features and chest CT), pathophysiology (Cole's vicious cycle hypothesis involving infection and inflammation causing tissue damage), etiologies (post-infectious, mucociliary disorders like cystic fibrosis, immunodeficiency, rheumatological conditions), and relationship to COPD (similar inflammation and airflow obstruction features). The document is intended to provide an overview of bronchiectasis for medical students.
This document provides an overview of interstitial lung diseases (ILDs). It discusses the protective mechanisms of the lung, pathogenesis of ILDs including different presentation patterns, classification of ILDs, diagnostic testing approaches, treatment options including drug therapy and pulmonary rehabilitation. Key points covered include common causes of different radiographic patterns seen on chest imaging for ILDs and rules for approaching a practical diagnosis of ILD based on clinical and imaging features.
Peripheral neuropathy refers to damage to peripheral nerves. There are three main types: mononeuropathy affecting a single nerve, mononeuritis multiplex affecting multiple nerves asymmetrically, and polyneuropathy affecting multiple nerves concurrently and symmetrically. Polyneuropathy can be classified as axonopathy, myelinopathy, or neuronopathy depending on whether the axons, myelin sheaths, or neurons are affected. Symptoms and signs include both negative symptoms like numbness and weakness as well as positive symptoms like tingling and pain. Evaluation involves taking a history and examining for patterns of onset, progression, fluctuations, and other systemic diseases. Diagnosis involves nerve conduction studies and sometimes nerve biopsies. Treatment focuses
Chronic fatigue syndrome is a condition characterized by severe fatigue lasting over 6 months that is not relieved by rest. It can include symptoms like muscle pain, headaches, sore throat, and cognitive difficulties. While the cause is unclear, potential contributing factors include infections, stress, and inactivity. Diagnosis involves ruling out other conditions and meeting criteria of fatigue plus other symptoms. Treatment focuses on cognitive behavioral therapy and graded exercise to manage symptoms, restore function, and prevent relapses. Prognosis is variable, but most patients see at least some improvement with treatment.
Chronic fatigue syndrome (CFS) is a disorder characterized by severe fatigue lasting over 6 months along with cognitive difficulties. It affects women more than men and those who are overweight and inactive. While the cause is unknown, it may be related to viral infections. The diagnosis is made after excluding other conditions and involves fatigue, impaired memory/concentration, sore throat, tender lymph nodes, muscle/joint pain, headaches, and unrefreshing sleep. Management focuses on symptom relief through analgesics, antidepressants, and sedatives as well as improving quality of life through sleep, rest, and relaxation techniques. Specific treatments have not proven effective.
This document provides an overview of chronic fatigue syndrome (CFS), including its symptoms, diagnosis, and living with the condition. CFS is a complex illness characterized by severe fatigue and other symptoms like muscle pain and cognitive impairment that are worsened by physical or mental activity. While the cause is unknown, diagnosis involves ruling out other conditions and having specific symptoms for at least 6 months. Managing CFS requires an individualized treatment plan and coping strategies, as living with a fluctuating condition can be difficult both physically and emotionally.
Post covid-19 syndrome, also known as long covid, refers to symptoms that can persist for weeks or months after recovery from the initial acute illness. While people are not infectious during this time, there is no agreed upon definition. A wide range of long-term symptoms have been reported, including fatigue, chest pain, muscle pain, loss of smell, and depression. Certain groups, such as older individuals, those who are obese, and people with diabetes or lung/kidney disease, appear to be at higher risk of developing long-term effects from covid-19.
This document discusses bronchiectasis, defined as abnormal permanent dilation of the bronchi. It covers the types (tubular, varicose, cystic), diagnosis (clinical features and chest CT), pathophysiology (Cole's vicious cycle hypothesis involving infection and inflammation causing tissue damage), etiologies (post-infectious, mucociliary disorders like cystic fibrosis, immunodeficiency, rheumatological conditions), and relationship to COPD (similar inflammation and airflow obstruction features). The document is intended to provide an overview of bronchiectasis for medical students.
This document provides an overview of interstitial lung diseases (ILDs). It discusses the protective mechanisms of the lung, pathogenesis of ILDs including different presentation patterns, classification of ILDs, diagnostic testing approaches, treatment options including drug therapy and pulmonary rehabilitation. Key points covered include common causes of different radiographic patterns seen on chest imaging for ILDs and rules for approaching a practical diagnosis of ILD based on clinical and imaging features.
Peripheral neuropathy refers to damage to peripheral nerves. There are three main types: mononeuropathy affecting a single nerve, mononeuritis multiplex affecting multiple nerves asymmetrically, and polyneuropathy affecting multiple nerves concurrently and symmetrically. Polyneuropathy can be classified as axonopathy, myelinopathy, or neuronopathy depending on whether the axons, myelin sheaths, or neurons are affected. Symptoms and signs include both negative symptoms like numbness and weakness as well as positive symptoms like tingling and pain. Evaluation involves taking a history and examining for patterns of onset, progression, fluctuations, and other systemic diseases. Diagnosis involves nerve conduction studies and sometimes nerve biopsies. Treatment focuses
Chronic fatigue syndrome is a condition characterized by severe fatigue lasting over 6 months that is not relieved by rest. It can include symptoms like muscle pain, headaches, sore throat, and cognitive difficulties. While the cause is unclear, potential contributing factors include infections, stress, and inactivity. Diagnosis involves ruling out other conditions and meeting criteria of fatigue plus other symptoms. Treatment focuses on cognitive behavioral therapy and graded exercise to manage symptoms, restore function, and prevent relapses. Prognosis is variable, but most patients see at least some improvement with treatment.
Post-covid symptoms can persist beyond three weeks for some patients. Common symptoms include cough, fatigue, shortness of breath, and joint pain. Tests may show lymphopenia or elevated biomarkers. Treatment focuses on managing symptoms, with breathing exercises and light exercise recommended. Some patients develop cardiopulmonary complications and require specialist referral. Ongoing symptoms like fatigue and neurological issues are still being studied.
1) Encephalitis is an acute inflammation of the brain that is usually caused by a viral infection. Children, the elderly, and those with weak immune systems are most at risk.
2) Diagnosis involves imaging tests like MRI and CT scans to view brain inflammation, as well as tests of cerebrospinal fluid and blood to identify potential viral causes.
3) Treatment depends on the severity and cause of the inflammation. Supportive care aims to help the body fight infection, while antiviral drugs may be given if a viral cause is identified.
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease characterized by obstructed airflow from the lungs. The main cause is long-term cigarette smoking which damages the lungs over time. Other irritants like secondhand smoke or air pollution can also contribute. Symptoms include difficulty breathing, chronic cough, and more frequent respiratory infections. Treatment focuses on smoking cessation to prevent further damage, along with medications, oxygen therapy, and lifestyle changes. Nurses educate patients on avoiding smoking and pollution to help manage the condition.
Chronic fatigue syndrome is characterized by severe, debilitating fatigue lasting over 6 months along with other symptoms like muscle pain and cognitive issues. The cause is unknown but may involve viral infections. Diagnosis is difficult due to the lack of definitive tests or features. Treatment focuses on symptom management through lifestyle changes, exercise therapy, and sometimes medications like antidepressants. Prognosis varies but most patients do not fully recover and treatment aims to improve functioning.
Chronic fatigue syndrome (CFS) is defined by persistent fatigue lasting at least 6 months accompanied by other specific symptoms. It is not caused by ongoing exertion and is not relieved by rest. CFS has no known cause but may be related to a previous infection. It commonly affects women in their 40s and 50s and is associated with overweight, inactivity, and stress. Diagnosis requires unexplained fatigue plus at least four of eight additional symptoms like memory issues, sore throat, and muscle or joint pain. Treatment focuses on cognitive behavioral therapy, graded exercise, activity management, and sometimes antidepressants or sleeping pills.
Tuberculous infection of the central nervous system (CNS) can occur via hematogenous spread or direct extension from a local infection. It most commonly manifests as tuberculous meningitis or tuberculomas. Tuberculous meningitis involves thick exudate in the subarachnoid space and can lead to hydrocephalus or ischemic infarcts. Tuberculomas appear as ring-enhancing lesions on imaging. Pott's disease is spinal tuberculosis that causes vertebral body collapse and kyphosis. Management involves antituberculous medications for at least 6-9 months.
Neurological manifestations are common in COVID-19, occurring in around 80% of hospitalized patients. The document discusses several neurological effects such as smell and taste disorders, encephalopathy, cerebrovascular disease, neuromuscular disorders, seizures, sleep disorders, and various acute neurological manifestations. The pathogenesis is multifactorial, involving direct viral invasion, immune dysfunction, coagulopathies, and the renin-angiotensin system.
Motor neuron diseases are a group of neurodegenerative disorders that affect motor neurons in the brain and spinal cord, leading to progressive muscle weakness. The most common type is amyotrophic lateral sclerosis (ALS), which affects both upper and lower motor neurons. Symptoms start in one area, such as weakness in the arms or slurred speech, and gradually spread. As motor neurons die, muscles waste away and it becomes difficult to move, swallow, breathe and speak. There is no cure and the cause is largely unknown, though some risk factors include age, sex, family history and head trauma. Treatment focuses on managing symptoms and maximizing function and comfort through supportive care, devices, therapy and medications like riluzole.
Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain and tenderness. It is more common in women than men. While pain is the primary symptom, it also involves fatigue, sleep issues, cognitive problems, anxiety and depression. There is no known cause but factors like genetics and abnormal pain processing in the central nervous system may play a role. Treatment involves lifestyle changes like exercise and stress management as well as medications like antidepressants. While not curable, some patients are able to adapt well through treatment, but a minority have severe, treatment-resistant symptoms.
This document discusses chronic obstructive pulmonary disease (COPD) exacerbations. It defines COPD and lists its main respiratory symptoms. It describes factors that can precipitate exacerbations like infections. An exacerbation is an acute worsening of COPD symptoms requiring additional treatment. The document outlines how to assess a patient experiencing an exacerbation by taking a history, doing a physical exam, and tests. It provides indications for hospitalization versus outpatient treatment and classifications of exacerbation severity. Management involves treating the current exacerbation and preventing future ones.
This document discusses idiopathic pulmonary fibrosis (IPF), a chronic, progressive fibrosing interstitial pneumonia of unknown cause associated with a histopathologic pattern of usual interstitial pneumonia (UIP). It defines IPF and outlines the diagnostic criteria, which involves ruling out known causes, abnormal pulmonary function tests, characteristic radiologic findings on high-resolution computed tomography (HRCT), and surgical lung biopsy showing UIP pattern. HRCT features that are consistent and inconsistent with UIP are described. Guidelines for management of IPF are provided, including recommendations for pirfenidone and nintedanib based on recent clinical trials. Lung transplantation is the only treatment that increases long-term survival for patients with IPF.
Bronchiectasis is a chronic, irreversible dilatation of the bronchi and bronchioles that can be caused by infectious or non-infectious factors. Common infectious causes include bacterial infections from pathogens like Pseudomonas aeruginosa, Hemophilus influenzae, and Staphylococcus aureus. Non-infectious causes include exposure to toxic substances, allergic bronchopulmonary aspergillosis, and primary ciliary dyskinesia. Symptoms include persistent cough, thick sputum production, shortness of breath, wheezing and clubbing of fingers. Diagnosis involves collecting a medical history, physical examination, blood tests, sputum examination and pulmonary function tests. Treatment options include
Motor neurons are neurons that control muscles and glands. Their cell bodies are located in the brainstem or spinal cord, and their axons project to muscles. Motor neuron disease (MND) refers to conditions where motor neurons degenerate, leading to muscle weakness and atrophy. The most common type is amyotrophic lateral sclerosis (ALS), where both upper and lower motor neurons are affected. In ALS, muscles weaken and waste away as motor neurons die, and symptoms may include limb weakness, bulbar problems like slurred speech, and respiratory issues. The disease progresses as motor neurons continue to deteriorate over time.
This document provides guidance on diagnosing and treating patients with asthma, COPD, or asthma-COPD overlap syndrome (ACOS). It outlines a step-wise approach including 1) determining if a patient has chronic airways disease, 2) making a syndromic diagnosis of asthma, COPD, or ACOS, 3) confirming with spirometry, 4) initiating initial treatment, and 5) referring for further testing if needed. Key points include distinguishing features of asthma and COPD, the overlapping characteristics of ACOS, and ensuring appropriate controller therapy is used depending on the diagnosis. The goal is to accurately diagnose this common problem to optimize treatment outcomes.
1) The document discusses various syndromes that can result from lesions or occlusions in different parts of the posterior circulation arteries that supply the brainstem and cerebellum.
2) Specific syndromes are described based on the location of the lesion, including PCA, vertebral artery, and basilar artery syndromes. Onset, signs and symptoms on both sides of the lesion are outlined.
3) Midbrain, pontine, and medullary syndromes are also detailed. Bilateral lesions causing Anton's syndrome and Balint's syndrome are mentioned. A variety of resulting neurological deficits are associated with different posterior circulation artery occlusions.
Interstitial lung disease (ILD) is a group of disorders causing scarring of the lungs. Idiopathic pulmonary fibrosis is the most common ILD, accounting for around half of cases. It generally affects older adults and smokers and causes shortness of breath, cough, and lung function decline. Diagnosis involves imaging, pulmonary function tests, and biopsy. Approved treatments are pirfenidone and nintedanib, which can slow disease progression, but prognosis remains poor with median survival of 3-4 years. Nonspecific interstitial pneumonia is another ILD that may be idiopathic or associated with connective tissue diseases.
Fibromyalgia is a rheumatic disorder characterized by chronic widespread muscle pain. It primarily affects women ages 30 to 50 and is diagnosed when a patient has 11 of 18 tender points. Conventional treatments like antidepressants may provide short-term relief but have side effects. Holistic treatments aim to address underlying causes like food allergies, infections, poor nutrition and sleep. Lifestyle changes like exercise, stress reduction and dietary modifications can help manage symptoms.
Respiratory Complication Of Rheumatic Diseasedrmomusa
This document discusses respiratory complications of rheumatic diseases. It covers causes of diffuse parenchymal lung disease including infections, drugs, and connective tissue diseases. Clinical evaluation involves assessing symptoms, signs, imaging like HRCT, lung function tests, and biopsies. Specific lung manifestations are discussed for diseases like rheumatoid arthritis, SLE, and scleroderma. Drugs that can cause interstitial lung disease or other pulmonary complications are also outlined. Future areas of research are mentioned.
Guillain-Barré syndrome is an acute inflammatory demyelinating polyneuropathy characterized by progressive muscle weakness and loss of reflexes. It is usually preceded by a gastrointestinal or respiratory infection and can cause paralysis. Treatment involves plasmapheresis or intravenous immunoglobulin to reduce antibodies, with most patients recovering fully or having minor deficits, but 5-10% having permanent disability and 3-8% dying despite intensive care.
A 14-year-old female presented with 7 years of hearing loss, 6 years of blurred vision, and 2 years of weakness in all four limbs. On examination, she had wasting and weakness of muscles, fasciculations, and involvement of cranial nerves including hearing loss. Tests showed a denervation pattern consistent with Madras Motor Neuron Disease variant, a rare subtype of motor neuron disease more common in younger Indians.
Diagnosis and Treatment of Psychosomatic Disorder (Educational Slides)Andri Andri
This is a standard presentation for teaching medical students and colleagues about psychosomatic disorder, its diagnosis and therapy. We hope by reading this slides, you will understand the nature of psychosomatic disorder and its current approach in therapy
Post-covid symptoms can persist beyond three weeks for some patients. Common symptoms include cough, fatigue, shortness of breath, and joint pain. Tests may show lymphopenia or elevated biomarkers. Treatment focuses on managing symptoms, with breathing exercises and light exercise recommended. Some patients develop cardiopulmonary complications and require specialist referral. Ongoing symptoms like fatigue and neurological issues are still being studied.
1) Encephalitis is an acute inflammation of the brain that is usually caused by a viral infection. Children, the elderly, and those with weak immune systems are most at risk.
2) Diagnosis involves imaging tests like MRI and CT scans to view brain inflammation, as well as tests of cerebrospinal fluid and blood to identify potential viral causes.
3) Treatment depends on the severity and cause of the inflammation. Supportive care aims to help the body fight infection, while antiviral drugs may be given if a viral cause is identified.
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease characterized by obstructed airflow from the lungs. The main cause is long-term cigarette smoking which damages the lungs over time. Other irritants like secondhand smoke or air pollution can also contribute. Symptoms include difficulty breathing, chronic cough, and more frequent respiratory infections. Treatment focuses on smoking cessation to prevent further damage, along with medications, oxygen therapy, and lifestyle changes. Nurses educate patients on avoiding smoking and pollution to help manage the condition.
Chronic fatigue syndrome is characterized by severe, debilitating fatigue lasting over 6 months along with other symptoms like muscle pain and cognitive issues. The cause is unknown but may involve viral infections. Diagnosis is difficult due to the lack of definitive tests or features. Treatment focuses on symptom management through lifestyle changes, exercise therapy, and sometimes medications like antidepressants. Prognosis varies but most patients do not fully recover and treatment aims to improve functioning.
Chronic fatigue syndrome (CFS) is defined by persistent fatigue lasting at least 6 months accompanied by other specific symptoms. It is not caused by ongoing exertion and is not relieved by rest. CFS has no known cause but may be related to a previous infection. It commonly affects women in their 40s and 50s and is associated with overweight, inactivity, and stress. Diagnosis requires unexplained fatigue plus at least four of eight additional symptoms like memory issues, sore throat, and muscle or joint pain. Treatment focuses on cognitive behavioral therapy, graded exercise, activity management, and sometimes antidepressants or sleeping pills.
Tuberculous infection of the central nervous system (CNS) can occur via hematogenous spread or direct extension from a local infection. It most commonly manifests as tuberculous meningitis or tuberculomas. Tuberculous meningitis involves thick exudate in the subarachnoid space and can lead to hydrocephalus or ischemic infarcts. Tuberculomas appear as ring-enhancing lesions on imaging. Pott's disease is spinal tuberculosis that causes vertebral body collapse and kyphosis. Management involves antituberculous medications for at least 6-9 months.
Neurological manifestations are common in COVID-19, occurring in around 80% of hospitalized patients. The document discusses several neurological effects such as smell and taste disorders, encephalopathy, cerebrovascular disease, neuromuscular disorders, seizures, sleep disorders, and various acute neurological manifestations. The pathogenesis is multifactorial, involving direct viral invasion, immune dysfunction, coagulopathies, and the renin-angiotensin system.
Motor neuron diseases are a group of neurodegenerative disorders that affect motor neurons in the brain and spinal cord, leading to progressive muscle weakness. The most common type is amyotrophic lateral sclerosis (ALS), which affects both upper and lower motor neurons. Symptoms start in one area, such as weakness in the arms or slurred speech, and gradually spread. As motor neurons die, muscles waste away and it becomes difficult to move, swallow, breathe and speak. There is no cure and the cause is largely unknown, though some risk factors include age, sex, family history and head trauma. Treatment focuses on managing symptoms and maximizing function and comfort through supportive care, devices, therapy and medications like riluzole.
Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain and tenderness. It is more common in women than men. While pain is the primary symptom, it also involves fatigue, sleep issues, cognitive problems, anxiety and depression. There is no known cause but factors like genetics and abnormal pain processing in the central nervous system may play a role. Treatment involves lifestyle changes like exercise and stress management as well as medications like antidepressants. While not curable, some patients are able to adapt well through treatment, but a minority have severe, treatment-resistant symptoms.
This document discusses chronic obstructive pulmonary disease (COPD) exacerbations. It defines COPD and lists its main respiratory symptoms. It describes factors that can precipitate exacerbations like infections. An exacerbation is an acute worsening of COPD symptoms requiring additional treatment. The document outlines how to assess a patient experiencing an exacerbation by taking a history, doing a physical exam, and tests. It provides indications for hospitalization versus outpatient treatment and classifications of exacerbation severity. Management involves treating the current exacerbation and preventing future ones.
This document discusses idiopathic pulmonary fibrosis (IPF), a chronic, progressive fibrosing interstitial pneumonia of unknown cause associated with a histopathologic pattern of usual interstitial pneumonia (UIP). It defines IPF and outlines the diagnostic criteria, which involves ruling out known causes, abnormal pulmonary function tests, characteristic radiologic findings on high-resolution computed tomography (HRCT), and surgical lung biopsy showing UIP pattern. HRCT features that are consistent and inconsistent with UIP are described. Guidelines for management of IPF are provided, including recommendations for pirfenidone and nintedanib based on recent clinical trials. Lung transplantation is the only treatment that increases long-term survival for patients with IPF.
Bronchiectasis is a chronic, irreversible dilatation of the bronchi and bronchioles that can be caused by infectious or non-infectious factors. Common infectious causes include bacterial infections from pathogens like Pseudomonas aeruginosa, Hemophilus influenzae, and Staphylococcus aureus. Non-infectious causes include exposure to toxic substances, allergic bronchopulmonary aspergillosis, and primary ciliary dyskinesia. Symptoms include persistent cough, thick sputum production, shortness of breath, wheezing and clubbing of fingers. Diagnosis involves collecting a medical history, physical examination, blood tests, sputum examination and pulmonary function tests. Treatment options include
Motor neurons are neurons that control muscles and glands. Their cell bodies are located in the brainstem or spinal cord, and their axons project to muscles. Motor neuron disease (MND) refers to conditions where motor neurons degenerate, leading to muscle weakness and atrophy. The most common type is amyotrophic lateral sclerosis (ALS), where both upper and lower motor neurons are affected. In ALS, muscles weaken and waste away as motor neurons die, and symptoms may include limb weakness, bulbar problems like slurred speech, and respiratory issues. The disease progresses as motor neurons continue to deteriorate over time.
This document provides guidance on diagnosing and treating patients with asthma, COPD, or asthma-COPD overlap syndrome (ACOS). It outlines a step-wise approach including 1) determining if a patient has chronic airways disease, 2) making a syndromic diagnosis of asthma, COPD, or ACOS, 3) confirming with spirometry, 4) initiating initial treatment, and 5) referring for further testing if needed. Key points include distinguishing features of asthma and COPD, the overlapping characteristics of ACOS, and ensuring appropriate controller therapy is used depending on the diagnosis. The goal is to accurately diagnose this common problem to optimize treatment outcomes.
1) The document discusses various syndromes that can result from lesions or occlusions in different parts of the posterior circulation arteries that supply the brainstem and cerebellum.
2) Specific syndromes are described based on the location of the lesion, including PCA, vertebral artery, and basilar artery syndromes. Onset, signs and symptoms on both sides of the lesion are outlined.
3) Midbrain, pontine, and medullary syndromes are also detailed. Bilateral lesions causing Anton's syndrome and Balint's syndrome are mentioned. A variety of resulting neurological deficits are associated with different posterior circulation artery occlusions.
Interstitial lung disease (ILD) is a group of disorders causing scarring of the lungs. Idiopathic pulmonary fibrosis is the most common ILD, accounting for around half of cases. It generally affects older adults and smokers and causes shortness of breath, cough, and lung function decline. Diagnosis involves imaging, pulmonary function tests, and biopsy. Approved treatments are pirfenidone and nintedanib, which can slow disease progression, but prognosis remains poor with median survival of 3-4 years. Nonspecific interstitial pneumonia is another ILD that may be idiopathic or associated with connective tissue diseases.
Fibromyalgia is a rheumatic disorder characterized by chronic widespread muscle pain. It primarily affects women ages 30 to 50 and is diagnosed when a patient has 11 of 18 tender points. Conventional treatments like antidepressants may provide short-term relief but have side effects. Holistic treatments aim to address underlying causes like food allergies, infections, poor nutrition and sleep. Lifestyle changes like exercise, stress reduction and dietary modifications can help manage symptoms.
Respiratory Complication Of Rheumatic Diseasedrmomusa
This document discusses respiratory complications of rheumatic diseases. It covers causes of diffuse parenchymal lung disease including infections, drugs, and connective tissue diseases. Clinical evaluation involves assessing symptoms, signs, imaging like HRCT, lung function tests, and biopsies. Specific lung manifestations are discussed for diseases like rheumatoid arthritis, SLE, and scleroderma. Drugs that can cause interstitial lung disease or other pulmonary complications are also outlined. Future areas of research are mentioned.
Guillain-Barré syndrome is an acute inflammatory demyelinating polyneuropathy characterized by progressive muscle weakness and loss of reflexes. It is usually preceded by a gastrointestinal or respiratory infection and can cause paralysis. Treatment involves plasmapheresis or intravenous immunoglobulin to reduce antibodies, with most patients recovering fully or having minor deficits, but 5-10% having permanent disability and 3-8% dying despite intensive care.
A 14-year-old female presented with 7 years of hearing loss, 6 years of blurred vision, and 2 years of weakness in all four limbs. On examination, she had wasting and weakness of muscles, fasciculations, and involvement of cranial nerves including hearing loss. Tests showed a denervation pattern consistent with Madras Motor Neuron Disease variant, a rare subtype of motor neuron disease more common in younger Indians.
Diagnosis and Treatment of Psychosomatic Disorder (Educational Slides)Andri Andri
This is a standard presentation for teaching medical students and colleagues about psychosomatic disorder, its diagnosis and therapy. We hope by reading this slides, you will understand the nature of psychosomatic disorder and its current approach in therapy
Fatigue is a common complaint defined as a feeling of tiredness and lack of energy. It can be acute or chronic lasting over 6 months. The document discusses the causes, evaluation, and management of fatigue. Psychological factors are involved in most cases of chronic fatigue. Evaluation involves taking a thorough history and physical exam to rule out underlying medical conditions. Treatment focuses on treating any identified causes, cognitive behavioral therapy, exercise, and antidepressants may help relieve symptoms in some cases. Chronic fatigue syndrome is a diagnosis of exclusion defined by persistent fatigue and additional symptoms lasting over 6 months. Its cause is unclear but may involve infections, immune dysfunction, or sleep disturbances.
This document discusses somatic symptom and related disorders. It defines psychological factors that can affect medical conditions by exacerbating symptoms or interfering with treatment. It provides qualifiers to describe the severity of these psychological influences. The key features and differential diagnosis of various somatic symptom disorders are outlined, including somatic symptom disorder, illness anxiety disorder, and factitious disorders. Screening tools like the PHQ-15 and SSS-8 are presented. Treatment approaches are emphasized, including scheduling regular appointments, educating patients, evaluating somatic symptoms, treating comorbid conditions, and using cognitive behavioral therapy and medication.
This document discusses medically unexplained physical symptoms (MUPS) and somatic symptom disorder. It defines MUPS as physical symptoms that exist without objective medical findings or explanations. Somatic symptom disorder is characterized by physical symptoms caused by psychological or emotional distress. The document reviews the epidemiology, risk factors, clinical features, diagnostic criteria, cultural influences, and approaches for evaluating and treating patients with somatic symptom disorder.
1) A study of mortality rates in patients with schizophrenia in Sweden found rates were 2-3 times higher than the general population, with suicide rates being particularly elevated.
2) Recovery from schizophrenia is possible for many patients with appropriate treatment, though a meta-analysis found only 13.5% of patients met strict recovery criteria.
3) Guidelines provide no clear consensus on the optimal duration of antipsychotic treatment for multi-episode schizophrenia. Long-term treatment aims to reduce relapse rates but risks include brain tissue reduction.
Therapeutic medical aid delivery in case of most widespread therapeutic diseasesEneutron
The document discusses medical rehabilitation, including its goals of recovering patients' functional abilities and work capacity. It describes the three periods of rehabilitation: early, late, and readaptation. Early rehabilitation focuses on diagnosis, treatment and lifestyle changes. Late rehabilitation uses physical therapy and exercises. Readaptation takes place at resorts or specialized centers using rehabilitation methods to restore work ability. The principles of rehabilitation emphasize early treatment, continuity of care, and a comprehensive individualized approach.
OVERVIEW OF SOMATOFORM DISORDERS AND ITS MANAGEMENT.pptxValentinaEmeruwa
Somatic symptom disorder is characterized by physical symptoms that cannot be fully explained by a medical condition, along with excessive thoughts about the symptoms. It has a prevalence of 5-7% and is more common in women. The causes are unclear but may involve a low tolerance for physical sensations combined with a tendency to misinterpret them as signs of illness. Treatment focuses on cognitive-behavioral therapy and antidepressants to reduce somatic, anxiety, and depressive symptoms and improve functioning.
Somatoform disorders are a group of mental disorders characterized by physical symptoms that cannot be fully explained by a general medical condition. Key features include physical complaints with no adequate medical explanation that cause significant distress or impairment. Somatization disorder involves multiple somatic complaints over several years, while conversion disorder involves neurological symptoms that are psychologically caused. Hypochondriasis involves excessive worry about having a serious illness despite medical reassurance. Treatment focuses on psychotherapy and treating any underlying mental health conditions.
The document discusses several somatoform and somatic symptom disorders from the DSM-IV and DSM-V. It summarizes the key disorders including: somatic symptom disorder, which involves preoccupation with physical symptoms and their severity; conversion disorder, where neurological or sensory symptoms cannot be explained medically and may be psychological in origin; and illness anxiety disorder, previously known as hypochondriasis, involving severe anxiety and worry about having a serious illness. It provides details on diagnostic criteria, epidemiology, clinical features, etiology, course, and treatment approaches for these disorders.
4. Baseline Assessment & WHO staging ICAPRev.pptxyakemichael
The document provides guidance on conducting a baseline assessment for patients with HIV/AIDS. It outlines that the baseline assessment includes: documenting a positive HIV test result, collecting medical history, conducting a physical exam including vital signs and clinical staging, performing laboratory tests including a CD4 count, and preparing an ART care plan for the patient. It describes the components that should be included in the medical history, physical exam, clinical staging, and baseline laboratory assessment.
Chronic fatigue syndrome (CFS) is a disabling illness characterized by persistent physical and mental fatigue. It can begin as early as age 5 and affects people of all backgrounds. Patients experience a substantial reduction in activity levels compared to before diagnosis. CFS is diagnosed based on severe fatigue and other symptoms lasting at least 6 months after other potential causes are ruled out. While the cause is unknown, potential contributing factors include infectious agents, immune system issues, neurological abnormalities, and psychiatric comorbidities. Treatment focuses on managing symptoms, gradually increasing physical and mental activity levels, cognitive behavioral therapy, and getting high quality sleep.
Hanipsych, functional recovery in depressionHani Hamed
This document discusses functional recovery in depression. It begins by providing statistics on the prevalence of depression and other psychiatric disorders worldwide. It then discusses various milestones in the treatment of depression such as response, remission, and relapse. While symptom remission is an important goal, it does not always translate to functional improvement. Factors like residual symptoms, impairment at work or home, and social/emotional functioning are important to patients. The document presents evidence that escitalopram treatment can significantly improve daily living and functional outcomes compared to other antidepressants.
This document discusses hepatitis and depression. It provides epidemiological data on hepatitis C virus (HCV) infection worldwide and discusses how depression is more common in HCV patients compared to the general population. It outlines the overlap in symptoms between HCV adverse effects and depression. The document then discusses risk factors for depression during HCV therapy, potential mechanisms including impacts on cytokines and the hypothalamic-pituitary axis, and treatment guidelines for managing depression in patients receiving HCV therapy including the use of antidepressants.
National Prize of Applied Sciences nominee Dr. Jorge Lolas Talhami and his research on “cyclical hysterotoxemia”. Featuring: Dr. Enrique Vazquez-Vera - MD, FACOG; Dr. Jorge Lolas Talhami; Amanda Parodi; and Yusnaiberth Rivero De Detraux.
Content presented by Dr. Enrique Vazquez-Vera - MD, FACOG at the 2015 NAPMDD National Conference 8/9/2015.
View the session video at: http://napmdd.org/denver2015nc/session-03.html
Become a member of NAPMDD at:
http://napmdd.org/join
Measuring the right outcomes in mental healthJohn Brazier
This talk presents the findings of an MRC study on whether the generic health measures of EQ-5D and SF-36 are valid in mental health. It uses mixed methods research (including interviews with service users) to show that these measures miss important ways in which mental health impacts on people's lives. It proposes 7 themes that seem to capture the important domains of recovery for people with mental health problems that provide the basis for a new generic outcome measure for mental health.
N.B. These slides were presented at the 20th Anniversary of the Centre for Mental and Physical Health Economics, 7th November 2013.
This study evaluated the efficacy and safety of lisdexamfetamine dimesylate (LDX) for binge eating disorder (BED) in adults. Participants were randomized to placebo or LDX doses of 30, 50, or 70 mg/day for 11 weeks. The primary outcome was reduction in binge eating days per week. Secondary outcomes included reductions in binge episodes, improvements on the Binge Eating Scale and Three-Factor Eating Questionnaire. LDX at 50 and 70 mg/day significantly reduced binge eating days and episodes compared to placebo. LDX also improved binge eating behaviors and attitudes on secondary measures. The most common side effects with LDX were decreased appetite, dry mouth, headache,
The possible adverse effects of long-term prednisolone use are:
- Susceptibility to infection
- Fluid retention
- Osteoporosis
- Muscle weakness and atrophy
- Delayed wound healing
Similar to Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: short clinical update (20)
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: short clinical update
1. Short Clinical Review
Chronic Fatigue Syndrome
Myalgic Encephalomyelitis
Philippe Persoons MD, PhD
Assistant Professor Katholieke Universiteit Leuven
Faculty of Medicine, Department of Neurosciences, Unit Mind-Body Research
Coordinator of the Multidisciplinary Diagnostic Center for ME/CFS, Leuven, Belgium
2. Overview
• What is the significance of (functional) fatigue
• Classification criteria of CFS/ME and characteristics of the illness
• Clinical diagnosis of CFS/ME
• Typical symptoms
• Etiology & Pathophysiology – hypotheses & experimental findings
• Stress Adaptability Model
• philippe.persoons@upckuleuven.be
4. Fatigue in Primary Care
• Fatigue: up to 25% of of primary care MD’s appointments
Komaroff A, 2015
5. A cluster of syndromes
characterized by
overlapping symptoms and
similar systemic vulnerabilities
“lumpers” versus “splitters”
discussion exists
Diagnosis can be dependent on
the consulted medical specialism
What about double diagnoses?
7. What's in a name?
that which we call a rose
By any other name
would smell as sweet;
8. What’s in a name…
CFS/ME: criticisms on proposed names
• Not classified in DSM-5: not a psychiatric disorder
• Chronic Fatigue Syndrome (CFS)
– too trivializing? Too all inclusive
– Subgroup of patients with less severe illness? Further Research is Needed (FRIN)
• Myalgic Encephalomyelitis (ME)
– “presumed” inflammation of the central nervous system (brain/spinal cord) with symptoms of muscle pain and fatigue
– no definite proof
• however recent research shows slightly increased inflammatory activity which correlates with the severity of the symptoms in severe
cases (intracerebral inflammation, e.g. activated microglia)
• Interchangeability with the name CFS remains open for discussion: differences between authors and patients (FRIN)
• Post-viral fatigue syndrome (ICD-11 – 8E49) https://icd.who.int/dev11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f569175314
– Parent Category: Other disorders of the nervous system advise for patients: go to neuro
– Includes: CFS, ME, epidemic neuromyasthenia, chronic fatigue (unspecific),…
– ICD-10: G93.3: CFS, benign myalgic encephalomyelitis http://apps.who.int/classifications/icd10/browse/2016/en#/G93.3
• Chronic Lyme’s disease
– no evidence of existence systematic/chronic Lyme infection – not classified in ICD-10 or ICD-11
• Systemic Exertion Intolerance Disease (SEID) – since 2015 (IOM)
– Not yet picked up in scientific community – criteria have not yet been used enough research (FRIN)
10. Explanation of markings on previous slide
• Oxford Criteria are crossed out because they are not accepted anymore as a basis to include CFS/ME
patients in research protocols, because they might be too inclusive, thus also including patients with
depression and other psychiatric disorders. They can’t be included in meta-analyses to assess the effect of
a certain treatment (e.g. in the Cochrane database, American Institute for Medicine, NICE, etc.)
• CDC = Centers for Disease Control and Prevention; CFS = chronic fatigue syndrome; IOM = Institute of
Medicine; ME = myalgic encephalomyelitis;
• SEID = systemic exertion intolerance disease.
• * Defined functional impairment by Short-Form Health Survey (SF-36) scores, fatigue by Multidimensional
Fatigue Inventory (MFI), and symptoms by
• Symptom Inventory Case Definition subscale.
• † All 3 required.
• ‡ Impairment in function, fatigue, and new onset included as 1 of the 3 required symptoms.
• § Onset may be gradual.
• Eight of 11 minor symptoms.
• ¶ Four or more symptoms present concurrently for ≥6 months.
• ** At least 1 from 3 of the 4 symptom categories (neurocognitive, pain, sleep, neurosensory/motor).
• †† At least 1 of 3 symptoms.
• ‡‡ At least 2 neurologic/cognitive manifestations.
• §§ At least 1 of 2 required.
• At least 2 cognitive manifestations.
• ¶¶ At least 1 energy production/transportation impairment (cardiovascular, pulmonary, thermostatic,
temperature).
• *** At least 1 symptom from 2 of the categories of autonomic, neuroendocrine, and immune
manifestations.
• ††† At least 1 symptom for ≥3 categories of immune, gastrointestinal, and genitourinary impairments.
• ‡‡‡ Orthostatic intolerance.
Haney et al. Ann Intern Med. 2015;162:834-840
11. Prevalence of CFS
• Diagnostic criteria according to the CDC-criteria 1994 (Fukuda)
– Prevalence 0.2 – 0.4% up to 2.5% (!) - ± 20 000-30 000 in Belgium
– 12 month incidence 0.015%
– Variabele prevalence due to the different diagnostic criteria, setting, study design
– Onset 35-45 y/o
– Women (65-75%) >> men
– 50% of the patients need specialized care
– Severe functional impairment
• Controversy: use of Canadian Consensus Criteria Biomedical(psychosocial) (?) view point
– DePaul Symptom Questionnaire
– Assessment of functioning by using the SF-36
– Better specificity: exclusion of treatable illnesses (especially psychiatric illnesses)
• Biopsychosocial view remains paramount in the assessment and management of patients
12. Biopsychosocial model briges “Health” and “Illness”
“The dominant model of disease today is
biomedical, and it leaves no room within its
framework for the social, psychological,
and behavioral dimensions of illness.
A biopsychosocial model is proposed that
provides a blueprint for research, a
framework for teaching, and a design for
action in the real world of health care.”
G. Engel. Science. 1977 Apr 8;196(4286):129-36
14. Difficult (differential) diagnosis
• Wide variety of case criteria / heterogenic sample
• No biomarkers – no diagnostic blood tests – no investegative tools
• Patients with severe functional impairment
• Very complex condition:
– high number of symptoms – complex to manage
– High number of co-morbidities (also psychiatric): stay alert for new diagnoses in CFS/ME patients!
• Time sensitive diagnostics
• Exclusion diagnosis exclusion of treatable medical conditions explaining fatigue
exclusion of treatable psychiatric conditions explaining fatigue
NO exclusion of psychiatric co-morbidities of CFS/ME
exclusion diagnoses (e.g. severe drug abuse)
if necessary additional assessment
15. Prognosis of CFS/ME
• Variable prognosis – improvement is possible
– Level below premorbid level of functioning
• Premorbid level of functioning rendered them ill!
• Therapeutically we try to achieve a level below the premorbid level of functioning
– Evolution of CFS (Cairns RH. Occup Med 2005)
• Recovery 5% (0-31%)
• Improvement during follow-up 40% (8%-63%)
• Back to work 8%-30%
• Deterioration of symptoms 5%-20%
– Spectrum of functional impairment – variable days: good – bad - crash
• Mild - reduced or adapted work
• Moderate - staying at home; unable to work, but still functioning somewhat
• Severe - bedridden
16. Increased risk factors for severity of ME/CFS
• Severity at time of onset
• Standard of early management of illness
– Late Dx – overexertion in early stages deterioration
• Mother with illness
• Comorbid fibromyalgia
18. Diagnosis of CFS/ME
• Problem: identifying CFS/ME patients correctly
– No biomarkers – investigative tools
– Large number of case criteria
– Co-morbidity
• Diagnosis by exclusion
– Exclusion of treatable diseases as cause for fatigue
• Tests are to rule out other conditions
• First treatment for any treatable condition
• If symptom cluster and functional impairment remains diagnosis can still be made
– Exclusion of certain psychiatric illnesses as possible cause for fatigue
– Criteria for CFS/ME
Bested & Marshall. Rev Environ Health 2015; 30(4): 223–249
19. Exclusion of treatable illnesses
Bested & Marshall. Rev Environ Health 2015; 30(4): 223–249
21. Suggested Routine Lab tests
Bested & Marshall. Rev Environ Health 2015; 30(4): 223–249
22. Extra tests – depending on the symptoms
Bested & Marshall. Rev Environ Health 2015; 30(4): 223–249
23. CDC Criteria of CFS (Fukuda, 1994)
Used in the Belgian CFS Multidisciplinary diagnostic convention
• Severe, persistent or returning fatigue > 6 months
• Not explained by an active medical illness, nor by certain psychiatric disorders,
which warrants a psychiatric screening (psychosis, psychotic depression, substance
abuse, cognitive disorder or eating disorder, type anorexia and bulemia nervosa)
• New or with a clear-cut start, not improved by rest
• Results in a significant decrease of activities and Quality of Life
• AND FOUR or MORE of the following symptoms which started at around the same
time and are currently present for > 6 months:
– Cognitive symptoms - Lymph node swelling/pain
– Sore throat - Myalgia
– Arthralgia (migratory) - New type headache
– Unrefreshing sleep - Post-exertional malaise (PEM)
Fukuda et al. Ann Intern Med. 1994; 121: 954-959
25. Typical Symptoms of CFS
FUKUDA
Canadian criteria symptoms (ANS, neuro-endocrine system, immune system
26. Typical symptoms: FATIGUE
• Fatigue
– Different from “normal” tiredness – “Wired fatigue” (fatigued with pumping adrenaline)
– Cognitive/mental and physical exhaustion
– General Malaise
– Significant reduction of activity level (about 50% or more)
– New onset
– Fatigue is a spectrum complaint, i.e. from mild, moderate, severe to completely bedridden
27. Typical symptoms: POST-EXERTIONAL MALAISE (PEM)
• PEM: severe physical – mental/cognitive fatigue post-exertion
– Often seen as distinguishing symptom in CFS/ME: patients feel exhausted after exertion
– Worsening of symptoms CFS/ME in general: crash
– Relatively minimal physical and/or cognitive-mental exertion
• E.g. after shower, doing light computer work, ADL
• Experience of worsening of concentration and memory problems (brain fog)
• “Leaden feeling” in body and limbs
– Recovery pathologically slow: > 24H to weeks – Crash (near immobilizing PEM)
– Patient can become bedridden
– Pathophysiological experimental biological correlates on group level
28. Typical symptoms: SLEEP DYSFUNCTION
• Sleep dysfunction: unrefreshing – drowsy wakefulness – always chronic
– “Skimming under the surface” – “tired but wired”
• more severe when Fibromyalgia is co-morbid
– Paradoxically often insomnia: difficulty falling asleep & staying asleep
• NO HYPERSOMNOLENCE (DDx fatigue) – exception sometimes in younger patients
• Often paradoxical insomnia (impression of not sleeping – “seeing every hour” – while sleeeping
• Indicative of overactive autonomous nervous system
– Restoring/improving sleep is important in recovery process
– What about doing a polysomnography?
• Not all functional sleep disorders!
• In case of suspected sleep-breathing disorder, e.g. OSAS (exlusion criterion for diagnosis)
• other sleep-wake disorders: narcolepsia, idiopathic hypersomnolence, RLS
29. Sleep pattern in CFS: alpha-delta sleep
• Thirty second polysomnogram epoch showing stage N3 delta sleep (black arrows) with overriding
alpha frequency (red arrows): alpha-delta sleep: associated with psychiatric illness, fibromyalgia,
CFS, CWP
Manu P et al. Alpha-delta sleep in patients with a chief complaint of chronic fatigue.
South Med J. 1994; 87: 465-70.
30. Typical Symptoms: PAIN (headache, myalgia, joint pain)
• Pain range: mild to severe – chronic
– Often overlap with Fibromyalgia (typically the new ACR criteria for 2010)
– Most likely central sensitisation plays an important role in pain experienced by CFS/ME patients
• Hyperalgesia
• Allodynie
Bourke et al. J Psychosom Res. 2015. 78: 228-236
31. Typical Symptoms: OTHER SYMPTOMS
• Cognitive symptoms – linked to fatigue severity
– Impaired attention (objectively) – subjectively) Concentration difficulties
– Memory difficulties – word finding difficulties
– “Brain fog” often experienced as very disabling
– Also linked with “high sensitivity” for sensory input/stimulation – irritability (all senses)
• Input/noise ratio < 1
• Can lead to emotional overload – anxiety – crash
• Flu-like symptoms/infection-like symptoms
– Possible due to failure of regulation of stress-response system
• Neuroendocrine system
• Immunological dysregulation
32. Symptoms to be considered from other Criteria
• Canadian criteria linked to pathophysiological research findings (group level)
1. Autonomic dysfunction manifestation – certain syndromes have been hypothesized
– Malfunctioning of the Autonomic Nervous System
• Orthostatism, Decreased heart rate variability (exercise intolerance?), Changes in sweat production
• Functional dyspepsia – IBS symptoms, Urinary problems, Sexual problems
• Vision problems
– Hypothetical syndromes (most likely part of dysfunctioning stress response system)
• Chronic Orthotstatic Intolerance
– neurally mediated hypotension (NMH)
– Postural orthostatic tachycardia syndrome (POTS)
– Delayed postural hypotension (DPH)
33. • Canadian criteria linked to pathophysiological research findings (group level)
2. Neuroendocrine manifestations
– Due to Hypothalamic-pituitary-adrenal (HPA) axis dysfunction
– Closely linked to ANS and immune system dysfunction (see pathophysiological mechanisms)
• Diurnal fluctuation of symptoms and fatigue
• Feeling of feverishness
• Weight change – change in appetite
• Loss of adaptability and tolerance for (chronic) biopsychosocial stress: recovery through HPA-axis fails
Symptoms to be considered from other Criteria
34. Symptoms to be considered from other criteria
• Canadian criteria linked to pathophysiological research findings (group level)
3. Immune activation (see pathophysiology)
– General malaise symptoms
– Flu-like symptoms – recurring PEM
– Feeling feverish
– Tender lymphadenopathy
– Recurrent sore throat possibly with non-exudative pharyngitis
4. Possible consequences on biopsychosocial level
• Possibly highly sensitive to medication and other chemicals/food
• Increased general sensitivity
• Increased sensitivity to psychological/psychiatric co-morbidity
• Increased social isolation
38. Etiology of CFS
• No specific etiology/caus(es) of CFS/ME has been identified
• Remains exclusion diagnosis
– No clinically diagnostic test
– No biomarker
• Often a pivotal period/illness/event (precipitating)
– Flu-like illness/viral infection/bacterial infection no recovery
• Prospective study: CFS in 11% of cases after array of viral and parasitical infections
– Burn-out or depression
– Allostatic load “Allostatic Crash”
39. Etiology of CFS
• CFS/ME is just like any other chronic illness a biopsychosocial illness. Thus, we can identify
1. Predisposing factors (e.g. genetics, but also probably epigenetics and pre-morbid behavior, etc.)
2. Precipitating factors (e.g. viral infection, burn-out, but also possibly life event, etc.)
3. Perpetuating factors (e.g. pathophysiological factors such as sleep disorders, inflammation, HPA-axis
disruption, but also the constant fight because of frustrations, etc.)
4. Protective factors
• The etiopathogenesis of CFS/ME is very complex and without a doubt multifactorial. It is in
the brain and in the body (quote of Ron Davis in “Unrest”). It is definitely not a psychiatric
illness, but given the chronicity and the profound impact of the illness, it is important not to
lose sight of the psychosocial aspects which CFS/ME entails.
• Both for researchers and patients, it is important not to confuse (1) the cause/etiology
(etiopathogenisis) of the illness, (2) the tipping point or precipitation of the illness and (3)
the subsequent remaining pathofysiologic findings which are part of the ongoing illness
process and which might be correlated to the prevalent symptoms of the illness or the level
of dysfunction.
40. Is CFS/ME not another expression of (atypical) depression ?
- Formal psychiatric assessment: NO
- Major depressive disorder: clear diagostic criteria: AVOLITION/ANHEDONIA
- CFS: no criteria for CFS – possibly as co-morbidity: LOSS OF ADAPTABILITY
- Differences in neuro-endocrine studies: NO
- Major depressive disorder: hypercortisolaemia CFS: hypocortisoleamia
- MDD: dexamethasone: ACTH ↗ CFS: DXT: ACTH ↘
- Treatment: NO
- MDD: responsive to antidepressants
- CFS: no response to antidepressive drugs
41. Stress Adaptation Model
Chronic Fatigue Syndrome reflects loss of adaptability
(B Van Houdenhove & P Luyten. J Intern Med 2010; 268 :249-51)
42. Multisystemic Risk factors &
Pathophysiological consequenses
Risk factors (predisposing)
- Genetic predisposition – female gender – family
members increases RR (mother with CFS RR = 2.7)
- Gene-environment interaction: EPIGENETICS
- BioPsychoSocial “Stress”
- Environmental interactions
Pathophysiological processes through
Stress Respons System (perpetuating)
- Autonomic Nervous System
- Hypothalamic-Pituitary-Adrenal axis
- Immune system
- Central Sensitisation
- Changes in gray matter volumes and connectome
43. Activation of the components of the Stress Response System (SRS)
Immune
system
Endocrine
System
ANS
44. Consistent findings
• CFS/ME is not a psychiatric illness
– However calling it a “biomedical illness” is going back in time before George Engel (1970) and the introduction of the
all important “biopsychosocial approach of all medical illnesses
– Functional somatic illness what does “functional” mean = disfunctional cooperation/communication between
different essential systems controlling our bodily functions, which are essentially operated by our central nervous
system
– High comorbidity with anxiety and depression
– most important mortality: suicide: SMR 6·85, 95% CI 2·22–15·98; p=0·002) (Roberts E et al. Lancet 2016)
• Multifactorial illness
– Possible trigger ?
– Stress Response System plays a role in at least the pathophysiology
• Relative Consistent Research findings on group level
1. Dysregulated immune system: aspecific low level immune activation (correlated with symptom severity); production
of pro-inflammatory cytokines
2. Disturbed function of the neuro-endocrine system (HPA-axis): hyporeactive with relatively low cortisol
3. Disturbed autonomous nervous system: sympathic dysregulation
45. 1. Dysfunction of the immune system in peripheral blood and CNS
• The evidence supports the finding of immune dysfunction in ME/CFS1
– Natural Killer cell function studies: reduction of NK cell numbers and function
• Predisposing signature?
• Result of initiating viral infection, thus unrelated to etiology of ME/CFS, i.e. part of pathophysiology
– Cytokines: altered cytokine levels in serum and cerebrospinal fluid – low consistency
• Role in cause or chronicity: cytokine-cytokine associations differ accoring to duraton²
• Recent study (Montoya et al, 2017 PNAS) confirmed increased TGF-beta to be increased (other studies:
IL-1AR, IL-6, IL-8, etc.) and an upward “trend” of pro-inflammatory cytokines with ME/CFS severity³
• NO BIOMARKERS found (yet?)
• Increased cytokines (possible increased inflammation) post-exercise
1. Mensah, F et al. (2017). Clin Neurophysiol 47(2), 131–138
2. Hornig M, et al (2015). Sci Adv; 1: e1400121: 1-10
3. Montoya, J. G. et al. PNAS, 2017: 105-19.
46. 1. Effect of moderate exercise on expression of sensory,
adrenergic and immune genes in CFS patiënts (Light et al. J Pain 2009)
47. 1. Cytokine co-expression networks in CFS
Cytokine co-expression networks were
constructed from the pair-wise mutual
information (MI) patterns found within
each subject group. Networks for HC
and CFS had visibly different topologies
(geometric arrangements). A weighted
spring-electrical embedding structurally
reveals the subject-subject (inset) and
cytokine-cytokine associations based on
measurements in 59 healthy control
subjects (A) and 40 CFS patients (B). All
edge weights are significant at p ≤ 0.01.
Separation of subjects was consistent
with their assignment to diagnostic
groups supporting the use of within-
group variation in the estimation of
mutual information for cytokine-
cytokine associations
Broderick G, et al. A Formal Analysis of Cytokine Networks in Chronic Fatigue Syndrome. Brain Behav Immun
2010;24(7): 1209–1217. doi:10.1016/j.bbi.2010.04.012.
48. 1. Dysfunction of the immune system: Neuroinflammation and
its consequences for the cognitive and affective functioning
(Nakatomi Y et al. J Nucl Med 2014; 55: 1-6)
• Activation of microglia or astrocytes is
related to neuroinflammation.
• The BPND values of 11C-(R)-PK11195
in the cingulate cortex, hippocampus,
amygdala, thalamus, midbrain, and
pons were 45%–199% higher in
CFS/ME patients than in HC
• CFS/ME patients, the BPND values of
11C-(R)-PK11195 in the amygdala,
thalamus, and midbrain positively
correlated with cognitive impairment
score, the BPND values in the
cingulate cortex and thalamus
positively correlated with pain score,
and the BPND value in the
hippocampus positively correlated
with depression score.
• Neuroinflammation is present in
widespread brain areas in
CFS/MEpatients and was
associated with the severity of
neuropsychologic symptoms.
49. 2. Neuroendocrine dysregulation
• Experimental findings illustrating dysfunction of the HPA-axis
– Reduced function (reduced “repair function”) with effects on adrenal, gonad and thyroid function
– Mild hypocortisolism, changed cortisol awakening response and attenuated diurnal variation
– Blunted DHEA response to ACTH injection despite normal basal levels
– Increased prolactin secretion/sensitivity for certain drugs (e.g. duloxetine, pregabaline)
50.
51. 3. Autonomic dysfunction
• Orthostatic intolerance
• Heart rate variability (HRV) is abnormal in groups of patients with ME/CFS with
increased sympathetic nervous system tone and decreased parasympathetic tone
• Low blood volume has been found in patients with ME/CFS by between 10% and
15% compared to HC
• Increased HR + reduced HRV in ME/CFS during sleep coupled with higher
norepinephrine levels and lower plasma aldosterone suggest a state of sympathetic
autonomic nervous system predominance
52. Other systems which might play a role
• Mitochondrial/energy production abnormalities
– Impairment of oxidative phosphorylation including decreased ATP production by mitochondria
reduced aerobic energy production + increased production lactic acid
• Oxidative & Nitrosative stress with consequences for TRYCAT pathways and central
and peripheral fatigue
54. Treatment modalities
CDC: There is no cure or approved treatment for myalgic encephalomyelitis/chronic
fatigue syndrome (ME/CFS). However, some symptoms can be treated or managed.
Treating these symptoms might provide relief for some patients with ME/CFS but not
others. Other strategies, like learning new ways to manage activity, can also be helpful.
55. Goals
• Improvement
– current symptoms
– functioning
– quality of life.
• Prevention
– Worsening of symptoms
– Development of psychopathology – high risk of suicide
– Iatrogenic/Dr. Google-induced/Quack-induced complications
• Coping with the emotional impact and grieve for the losses
• Validation of the patient’s experience and symptoms
– acknowledging the patient’s illness: ME/CFS. Having a diagnosis might the beginning of healing
for many patients who have been told “it’s all in your head” for many years.
– Acceptance of symptoms: ACT
56. Managment strategies
• Establish positive reinforcing, supportive therapeutic relationship with the patient
• Educate patient and family about the condition
• Collaborate with patient to develop an individualized treatment program
• Empower the patient to trust his/her own experiences and use his/her symptoms as
early warning devices to avoid PEM relapse/crash
• Symptomatic treatment begins with helping patients cope with their most
debilitating symptom
• Treatment = currently management of symptoms
58. Individualized Management of symptoms
• Fatigue – minimalize risk of Post-exertional Malaise (PEM)
– Energy conservation exercise – exercise program tailored to individual patient
– GET Risk PEM in CFS ? controversial no more classe 1 evidence
• Mixed evidence & results1,2
– “Adapted pacing”™: physical energy conservation:
• planning a day around breaks/rests, but not as rigourous as classic Pacing
• within energy envelope – but as active as possible in between w/o overexertion/crash
• Discovering new physical bounderies – putting the needs of their body first
• Plan exciting, relaxing, fun activities – adjust your life
– Medication: e.g. stimulants: e.g. methylphenidate³ very occasionally PEM
• To manage exceptional events
1. McCrone et al. PLoS One 2012
2. Bested & Marshall. Rev Environ Health 2015; 30(4): 223–249
3. Blockmans et al. Am J Med 2006
60. Management of other symptoms
• Sleep
– Sleep hygiene
– Mind the circadian rhythm – “Zeitgebers”
– Medication with care
• Pain – co-morbid fibromyalgia – migraines – very sensitive to medication
– Needs to be managed – individually tailored
– OTC medication often less helpful
– Alternative medication with analgesic properties (e.g. anticonvulsants, antidepressants)
– Be careful with narcotic medication
– If necessary: pain specialist
61. Management of other symptoms
• Psychiatric disorders: high risk: depressive disorder, anxiety disorder
– Good differential diagnosis between CFS/ME and Psychiatric disorders, e.g. HADS, PHQ-9
• Depressive disorder: often severe anhedonia, avolition – not in ME/CFS
• ME/CFS: loss of health – difficult adaptation process
– However high risk of co-morbidity major depressive disorder, anxiety disorder, other
– In CFS: suicide is most common cause for mortality
– Treatment: lege artis – e.g. with antidepressants also useful in pain
• Venlafaxine 150mg or more (max 300mg)
• Duloxetine 60mg or more (max 120mg)
• Go low Go slow
62. Management of symptoms
• Cognitive behavioral therapy (CBT) for ME/CFS – Evidence Based Treatment ?
– Therapy with “clearest evidence” for ME/CFS to guide the path to recovery – NOT curative
– Psychotherapy: cognitive and behavioral interventions
– Aim: changing cognitive processes: increased self-efficacy with respect to fatigue, reduced
symptom focus, symptom perception, increased perceived activity
– Currently highly controversial, together with Graded exercise therapy (GET)
• See biological findings
• Many studies based on Oxford criteria which might have been too inclusive
• Falsly seen as a “cure” by some groups
• See as “beneficial” by other groups because it can reducse the emotional drain of negative emotions
• Thus “emotional energy conservation”
• To be continued Chalder T et al.Lancet Psychiatry 2015
Knoop H. Lancet Pscyhiatry 2015
63. Experimental therapy: Rituximab in ME/CFS
(Fluge et al, PLOS one 2011 and 2015)
• B cell depletion therapy in ME/CFS using rituximab (chimeric monoclonal antibody)
- decrease the number of harmful (auto)antibodies produced by
daughter plasmablasts or plasma cells
- may also act by depleting virus infected B cells in a direct
manner
- Results
- Single treatment of rituximab (2 infusions 2 weeks apart).
- Lasting improvement in operator and self-reported fatigue
scores, as well as other symptoms, in 10 out of 15 patients
(67%) in the rituximab group and two out of 15 (13%) in
the placebo group
- response was found to be ‘‘delayed’’ with clinical
improvement starting from 2—7 months
- Open label phase II: subset of patients had sustained
clinical response to prolonged B-cell depletion (11/29)
66. Chronic Fatigue Syndrome/ME
• Controversial but real albeit heterogenic spectrum syndrome
• Syndrome with predisposing, precipitating and perpetuating factors
• Clinical diagnosis and an exclusion diagnosis: medical – psychiatric
• Experimental findings are not specific and selective for CFS/ME: no diagnostic tests
• FRIN: both fundamental etiopathogenetic and toward effective management
• Individual management of the patient is necessary
Editor's Notes
WHO:
8E49 Postviral fatigue syndrome
Parent
Other disorders of the nervous system
Show all ancestors up to top
ICD-10 : G93.3
Inclusions
Benign myalgic encephalomyelitis
chronic fatigue syndrome
ME/CFS have been maligned and told they did not have a real physical illness and that it was “all in their head”. The IOM acknowledged this in the report Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness and described it as “a disease characterized by profound fatigue, cognitive dys- function, sleep abnormalities, autonomic manifestations, pain, and other symptoms that are made worse by exer- tion of any sort. ME/CFS can severely impair patients’ ability to conduct their normal lives.” (8).
The new SEID criteria were not assessed with patient data sets and controls. Analysis of 796 CFS patients BioBank samples found that the new SEID criteria selected more patients who had less impairment and fewer symp- toms than several other criteria. It excluded symptoms of pain and immune system dysfunction. Also, SEID does not exclude “individuals from major depressive disorder illness groups as well as other medical illnesses” (9, 10). The SEID criteria is similar to the 1994 Fukuda CFS crite- ria and the 1991 Oxford CFS criteria which include other
CDC = Centers for Disease Control and Prevention; CFS = chronic fatigue syndrome; IOM = Institute of Medicine; ME = myalgic encephalomyelitis;
SEID = systemic exertion intolerance disease.
* Defined functional impairment by Short-Form Health Survey (SF-36) scores, fatigue by Multidimensional Fatigue Inventory (MFI), and symptoms by
Symptom Inventory Case Definition subscale.
† All 3 required.
‡ Impairment in function, fatigue, and new onset included as 1 of the 3 required symptoms.
§ Onset may be gradual.
Eight of 11 minor symptoms.
¶ Four or more symptoms present concurrently for ≥6 months.
** At least 1 from 3 of the 4 symptom categories (neurocognitive, pain, sleep, neurosensory/motor).
†† At least 1 of 3 symptoms.
‡‡ At least 2 neurologic/cognitive manifestations.
§§ At least 1 of 2 required.
At least 2 cognitive manifestations.
¶¶ At least 1 energy production/transportation impairment (cardiovascular, pulmonary, thermostatic, temperature).
*** At least 1 symptom from 2 of the categories of autonomic, neuroendocrine, and immune manifestations.
††† At least 1 symptom for ≥3 categories of immune, gastrointestinal, and genitourinary impairments.
‡‡‡ Orthostatic intolerance.
A 30 year-old Army veteran with a past medical history significant for chronic lumbar back pain stemming from a fall-from-height injury sustained in 2006 was referred to the sleep laboratory for evaluation of chronic fatigue and excessive daytime hypersomnolence. His Epworth sleepiness scale score was 16. He denied a history of snoring and witnessed apnea. Body Mass Index (BMI) was 25.7 kg/m2. His main sleep related complaints were frequent nocturnal arousals, poor sleep quality, un-refreshing sleep, prolonged latency to sleep onset, and nightmares. An In-lab attended diagnostic polysomnogram was performed. Sleep efficiency was reduced (73%) and overall arousal index was not significantly elevated (3.2 events/hour). The sleep study showed rapid eye movement (REM) related sleep disordered breathing that did not meet diagnostic criteria for sleep apnea. There was no evidence for period limb movement disorder. However, the study was significant for alpha wave intrusion in stage N2 non-REM and stage N3 delta sleep. Example epochs are shown in figures 1 and 2.
Alpha wave activity is characteristic of drowsy wakefulness and represents the background electro-encephalographic (EEG) pattern of the occipital region of the brain. Alpha activity occurs when individuals close their eyes and the occipital region loses visual stimulus. Alpha-Delta sleep is defined by a mixture of 5-20% delta waves combined with alpha-like rhythms that are interspersed among the delta waves and was first described in 1973 by Hauri & Hawkins (1). Alpha-Delta sleep has been associated with various neuro-psychiatric conditions including schizophrenia, depression, schizoaffective disorder, narcotic addiction, temporal epilepsy, fibromyalgia, chronic fatigue syndrome, and chronic pain syndrome (1,2). Alpha wave intrusion has also been shown to occur in stage N2 non-REM sleep in individuals with fibromyalgia and chronic pain. Poor sleep quality is often reported in individuals with complaints of chronic pain. It is suggested that alpha wave intrusion correlates with pain severity and can be used as a monitor to assess response to therapy (3).
Fig. 1. a&b: Spinal sensitisation: Ascending and descending mechanisms involved in pain control. a: A painful stimulus is able to activate peripheral nociceptors that in turn activate
nociceptive neurons in the superficial dorsal horn of the spinal cord. Lamina II neurons project in the spinoreticular and spinothalamic tracts to the brainstemand higher cortical centres.
At the level of the brainstem, descending inhibitorymechanisms are activated involvingmonoamine and opioid neurotransmitter systems (conditioned painmodulation) in tandem with
a reduction in descending facilitatory mechanisms. In turn these act to reduce pain and prevent its spread to neighbouring areas. With this system intact, upon repeat stimulation a
habituation response is facilitated, whereby the same stimulus intensity results in the same or less painful sensation. b: In a sensitised state, non-painful stimuli are able to activate
nociceptive specific dorsal horn cells. A clinical consequence of this is the experience of pain on non-painful stimulation — allodynia. This in turn results in greater activity in ascending
pathways to the brainstem. There is a reduced response in descending inhibitory pathways, combined with an increased or no change in response in descending facilitatory pathways,
such as that more pain related activity ascends but without a compensatory rise in descending pain inhibition or decline in pain facilitation. This is clinically detectable as increased
pain sensitivity and widespread hyperalgesia.
Chronic Orthostatic Intolerance: is the inability to sustain upright activity including: sitting, standing or walking. The most symptoms in ME/CFS include: over- whelming exhaustion, an urgency to lie down, feeling faint, mental confusion, malaise and the worsening of other symptoms. The symptoms are relieved when reclin- ing. Patients, like Case CL, often develop these symptoms when standing waiting in line e.g. at the bank.
Documentation of Orthostatic Intolerance: can be done in the office setting by first setting a baseline blood pressure by measuring the BP after the patient lies supine for 5 min. Next the patient stands still for 10 min and does not move their legs. BP and heart rate are taken every 2 min for 10 min. Symptoms such as fatigue, lightheadedness, nausea, warmth, shortness of breath, headache, pain, reduced con- centration/brain fog are recorded on a 0–10 scale when the patient is supine and then every few minutes when stand- ing still. The patient must be monitored at all times due to the possibility of syncope and falling injuries. A positive test documents a drop in blood pressure, increase in heart rate, color or volume changes in the lower legs or the pres- ence of symptoms of orthostatic intolerance.
Subtypes of Chronic Orthostatic Intolerance:
a. Neurally mediated hypotension (NMH) is an abnor- mality in the regulation of blood pressure during upright posture. There is a drop in systolic BP of 20–25 mm Hg (compared to the BP measured when the person is lying flat) when standing still. Symptoms may include light- headedness, headedness, dizziness, pressure-like chest pain over the left chest, visual changes, weakness, slowed verbal response, pallor, an urgency to lie down and syncope.
b. Postural orthostatic tachycardia syndrome (POTS) is present when the heart rate increases by 30 beats per minute (bpm) for adults, or 40 bpm for adolescents, or if it reaches 120 bpm or higher over the first 10 min of standing. Symptoms may include: lightheadedness, dizziness, nausea, fatigue, tremor, irregular breath- ing, headaches, visual changes, sweating, and rarely syncope. POTS is an abnormality in the autonomic regulation of heart rate; the heart itself is usually nor- mal. The increased heart rate may be accompanied by a fall in blood pressure, neurally mediated hypoten- sion, while standing. The two conditions, POTS and NMH, often are found together and can cause chronic, daily, orthostatic symptoms.
c. Delayed postural hypotension happens when there is a delayed drop in blood pressure 10 min or more after the patient stands.
Jennifer Brea's Sundance award-winning documentary, Unrest, is a personal journey from patient to advocate to storyteller. Jennifer is twenty-eight years-old, working on her PhD at Harvard, and months away from marrying the love of her life when a mysterious fever leaves her bedridden. When doctors tell her it's "all in her head," she picks up her camera as an act of defiance and brings us into a hidden world of millions that medicine abandoned.
In this story of love and loss, newlyweds Jennifer and Omar search for answers as they face unexpected obstacles with great heart. Often confined by her illness to the private space of her bed, Jennifer connects with others around the globe. Like a modern-day Odysseus, she travels by Skype into a forgotten community, crafting intimate portraits of four other families suffering similarly. Jennifer Brea's wonderfully honest and humane portrayal asks us to rethink the stigma around an illness that affects millions. Unrest is a vulnerable and eloquent personal documentary that is sure to hit closer to home than many could imagine.
Genetics:
- Twin studies show a higher concordance in monozy- gotic (55%) compared to dizygotic (19%) twins (51–54).
differential expression of 88 human genes in patients with ME/CFS. Clustering of quantitative PCR data from patients with ME/CFS reveals seven distinct sub- types with distinct differences in Medical Outcomes Survey Short Form-36 scores, clinical phenotypes and severity (55)
– A study was done using single-nucleotide polymor- phism (SNP) analysis to identify subtypes of ME/CFS with distinct clinical phenotypes. Twenty one SNPs were significantly associated with ME/CFS compared with depressed and normal groups. One hundred and forty eight SNP alleles had a significant association with one or more ME/CFS subtypes (56).
NK CELLS: come from studies of natural killer (NK) cell function. The NK cell is a type of cyto- toxic lymphocyte and is part of the innate immune system. NK cells play a key role in the earliest stages of recognition of virally infected cells and host rejection of transformed cells. NK cells can also secrete cytokines which can influ- ence other cells of the adaptive immune system
Cytokines: broad category of small proteins that are important in cell signalling, predominantly as communica- tors between cells of the immune system, and primarily important in modulating the balance between humoral and direct cell mediated immune responses.
Figure 2.
Amount of mRNA for ASIC3, P2X4, P2X5, and TRPV1 expressed as fold increases relative to baseline levels at each of the times indicated before (baseline) and after the end of 25 minutes of moderate exercise. * Indicates P< 0.05 compared to control subjects for the area under curve (AUC) of mRNA across all time points after exercise. Faint dotted line indicates the baseline levels
Figure 3.
Amount of mRNA for α-2A, β-1, β-2 adrenergic receptors and catechol-o-methyl-transferase (COMT) relative to baseline levels. * Indicates P< 0.05 compared to control subjects for the area under curve (AUC) of mRNA across all time points after exercise. Faint dotted line indicates the baseline levels
Figure 4.
Amount of mRNA for IL6, TNFα, IL10, TLR4, CD14 relative to baseline levels. * Indicates P< 0.05 compared to control subjects for the area under curve (AUC) of mRNA across all time points after exercise. Faint dotted line indicates the baseline levels
NIH Public Access
Author Manuscript J Pain. Author manuscript; available in PMC 2010 October 1.
Published in final edited form as: J Pain. 2009 October ; 10(10): 1099–1112. doi:10.1016/j.jpain.2009.06.003.
Moderate exercise increases expression for sensory, adrenergic and immune genes in chronic fatigue syndrome patients, but not in normal subjects
Alan R. Light1,2, Andrea T. White3, Ronald W. Hughen1, and Kathleen C. Light1 1 Dept. of Anesthesiology, University of Utah Salt Lake City, UT
2 Dept. of Neurobiology and Anatomy, University of Utah Salt Lake City, UT 3 Exercise and Sport Science, University of Utah Salt Lake City, UT
Abstract
Chronic Fatigue Syndrome (CFS) is characterized by debilitating fatigue, often accompanied by widespread muscle pain that meets criteria for Fibromyalgia Syndrome (FMS). Symptoms become markedly worse after exercise. Previous studies implicated dysregulation of the sympathetic nervous system (SNS), and immune system (IS) in CFS and FMS. We recently demonstrated that Acid Sensing Ion Channel (likely ASIC3), purinergic type 2X receptors (likely P2X4 and P2X5), and the transient receptor potential vanilloid type 1 (TRPV1) are molecular receptors in mouse sensory neurons detecting metabolites that cause acute muscle pain and possibly muscle fatigue. These molecular receptors are found on human leukocytes along with SNS and IS genes. Real-time, quantitative PCR showed that 19 CFS patients had lower expression of β-2 adrenergic receptors but otherwise did not differ from 16 controls before exercise. After a sustained moderate exercise test, CFS patients showed greater increases than controls in gene expression for metabolite detecting receptors ASIC3, P2X4 and P2X5, for SNS receptors α-2A, β-1, β-2 and COMT, and IS genes for IL10 and TLR4 lasting from 0.5–48 hours (P< .05). These increases were also seen in the CFS subgroup with comorbid FMS and were highly correlated with symptoms of physical fatigue, mental fatigue and pain. These new findings suggest dysregulation of metabolite detecting receptors as well as SNS and IS in CFS and CFS-FMS.
Perspective—Muscle fatigue and pain are major symptoms of CFS. Following moderate exercise, CFS and CFS-FMS patients show enhanced gene expression for receptors detecting muscle metabolites and for SNS and IS, which correlate with these symptoms. These findings suggest possible new causes, points for intervention and objective biomarkers for these disorders
Figure 1: Cytokine co-expression networks were constructed from the pair-wise mutual information (MI) patterns found within each subject
group. Networks for HC and CFS had visibly different topologies (geometric arrangements). A weighted spring-electrical embedding structurally
reveals the subject-subject (inset) and cytokine-cytokine associations based on measurements in 59 healthy control subjects (A) and
40 CFS patients (B). All edge weights are significant at p ≤ 0.01. Separation of subjects was consistent with their assignment to diagnostic
groups supporting the use of within-group variation in the estimation of mutual information for cytokine-cytokine associations (73).
Diagram used with permission.
Broderick G, Fuite J, Kreitz A, Vernonb SD, Klimas N, Fletcherd MA. A Formal Analysis of Cytokine Networks in Chronic Fatigue Syndrome.
Brain Behav Immun 2010;24(7): 1209–1217. doi:10.1016/j.bbi.2010.04.012.
Activation of microglia or astrocytes is related to neuroinflammation. 11C-(R)-PK11195 is a ligand of PET for a translocator protein that is expressed by activated microglia or astrocytes. We used 11C-(R)-PK11195 and PET to investigate the existence of neuroinflammation in
CFS/ME patients. Methods: Nine CFS/ME patients and 10 healthy
controls underwent 11C-(R)-PK11195 PET and completed questionnaires
about fatigue, fatigue sensation, cognitive impairments, pain,
and depression. To measure the density of translocator protein, nondisplaceable
binding potential (BPND) values were determined using
linear graphical analysis with the cerebellum as a reference region.
Results: The BPND values of 11C-(R)-PK11195 in the cingulate cortex,
hippocampus, amygdala, thalamus, midbrain, and pons were 45%–
199% higher in CFS/ME patients than in healthy controls. In CFS/ME
patients, the BPND values of 11C-(R)-PK11195 in the amygdala, thalamus,
and midbrain positively correlated with cognitive impairment
score, the BPND values in the cingulate cortex and thalamus positively
correlated with pain score, and the BPND value in the hippocampus
positively correlated with depression score.Conclusion:Neuroinflammation
is present inwidespread brain areas in CFS/MEpatients and
was associated with the severity of neuropsychologic symptoms.
Evaluation of neuroinflammation in CFS/ME patients may be essential
for understanding the core pathophysiology and for developing
objective diagnostic criteria and effective medical treatments.
unpublished observation of a patient showing unex- pected and markedly improved ME/CFS symptoms while being treated with immunosuppression for non-Hodgkin’s lymphoma, Fluge et al. reasoned that the mechanism induc- ing the symptoms of ME/CFS may have involved B cells. They followed up their hypothesis by the open label treatment of a further two ME/CFS patients with rituximab and again, the patients remarkably showed signs of improvement in all their symptoms
SUBGROUP: AUTO-IMMUNE DISEASE?
why and who will respond? The prolonged effect occurred when peripheral B cells were relatively absent from the periphery and new B cells prevented from exiting the bone marrow. Response to rituximab-based therapy in autoimmunity is usually asso- ciated with the presence of pathogenic autoantibodies produced by short-lived plasmablasts generated from either naïve B cells constantly entering the circulation or from the rapid differentiation to autoantibody production from memory B cells. Protective immunity is largely retained as long-term memory resides in long-lived plasma cells, which are not depleted by rituximab. The delay in improvement following induction of depletion may also suggest that in
ME/CFS patients’ antibodies and their parent B cells might be involved.
Autoantibo